Treatment-emergent adverse events were reported by 22% of the patients receiving placebo and by 65, 73, 86 and 84% of patients receiving 50, 100, 200 and 400mg lasmiditan, respectively. The most common adverse events seen in the lasmiditan groups related to the nervous system. Most reported events of heaviness were localized to the limbs. Chest symptoms characteristic of triptan use were rare, occurring with a similar frequency in the placebo and active groups. Adverse events with a total incidence of >5% of patients in the study are as follows:
One serious adverse event occurred in the study – moderate dizziness in a female patient receiving 200mg lasmiditan. The patient recovered without sequelae.
There were no clinically significant changes in laboratory pa- rammers, ECGs or vital signs.